CN100491396C - 选择性环肽 - Google Patents

选择性环肽 Download PDF

Info

Publication number
CN100491396C
CN100491396C CNB018150284A CN01815028A CN100491396C CN 100491396 C CN100491396 C CN 100491396C CN B018150284 A CNB018150284 A CN B018150284A CN 01815028 A CN01815028 A CN 01815028A CN 100491396 C CN100491396 C CN 100491396C
Authority
CN
China
Prior art keywords
lys
asp
phe
hydrogen
trp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB018150284A
Other languages
English (en)
Chinese (zh)
Other versions
CN1451017A (zh
Inventor
陈立
A·W·H·张
崔信洁
W·丹霍
J·斯威斯托克
王跃
K·A·亚安洛夫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of CN1451017A publication Critical patent/CN1451017A/zh
Application granted granted Critical
Publication of CN100491396C publication Critical patent/CN100491396C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • C07K14/68—Melanocyte-stimulating hormone [MSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CNB018150284A 2000-08-30 2001-08-21 选择性环肽 Expired - Fee Related CN100491396C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22918400P 2000-08-30 2000-08-30
US60/229,184 2000-08-30

Publications (2)

Publication Number Publication Date
CN1451017A CN1451017A (zh) 2003-10-22
CN100491396C true CN100491396C (zh) 2009-05-27

Family

ID=22860145

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB018150284A Expired - Fee Related CN100491396C (zh) 2000-08-30 2001-08-21 选择性环肽

Country Status (35)

Country Link
US (1) US7045591B2 (https=)
EP (1) EP1315750B1 (https=)
JP (1) JP4217069B2 (https=)
KR (1) KR100483300B1 (https=)
CN (1) CN100491396C (https=)
AR (2) AR030504A1 (https=)
AT (1) ATE353918T1 (https=)
AU (2) AU2001284026B2 (https=)
BR (1) BR0113637A (https=)
CA (1) CA2420058C (https=)
CY (1) CY1106562T1 (https=)
CZ (1) CZ2003584A3 (https=)
DE (1) DE60126624T2 (https=)
DK (1) DK1315750T3 (https=)
EC (1) ECSP034503A (https=)
ES (1) ES2280393T3 (https=)
HR (1) HRP20030126B1 (https=)
HU (1) HUP0303078A3 (https=)
IL (2) IL154575A0 (https=)
JO (1) JO2454B1 (https=)
MA (1) MA27681A1 (https=)
MX (1) MXPA03001721A (https=)
MY (1) MY137457A (https=)
NO (1) NO20030916D0 (https=)
NZ (1) NZ523989A (https=)
PA (1) PA8527201A1 (https=)
PE (1) PE20020483A1 (https=)
PL (1) PL366630A1 (https=)
PT (1) PT1315750E (https=)
RU (1) RU2239642C1 (https=)
SI (1) SI1315750T1 (https=)
TW (1) TWI248941B (https=)
WO (1) WO2002018437A2 (https=)
YU (1) YU15603A (https=)
ZA (1) ZA200301015B (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106496005A (zh) * 2016-10-20 2017-03-15 上海毕得医药科技有限公司 一种4‑(4‑氯苯基)环己酮的合成方法
CN106496008A (zh) * 2016-10-20 2017-03-15 上海毕得医药科技有限公司 一种合成4‑(4‑氯苯基)环己酮的方法

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6960646B2 (en) * 2001-07-12 2005-11-01 Merck & Co., Inc. Cyclic peptides as potent and selective melanocortin-4 receptors agonists
US7456184B2 (en) 2003-05-01 2008-11-25 Palatin Technologies Inc. Melanocortin receptor-specific compounds
US7732451B2 (en) 2001-08-10 2010-06-08 Palatin Technologies, Inc. Naphthalene-containing melanocortin receptor-specific small molecule
US7655658B2 (en) 2001-08-10 2010-02-02 Palatin Technologies, Inc. Thieno [2,3-D]pyrimidine-2,4-dione melanocortin-specific compounds
AU2002331064B2 (en) 2001-08-10 2007-08-23 Palatin Technologies, Inc. Peptidomimetics of biologically active metallopeptides
US7354923B2 (en) 2001-08-10 2008-04-08 Palatin Technologies, Inc. Piperazine melanocortin-specific compounds
US7718802B2 (en) 2001-08-10 2010-05-18 Palatin Technologies, Inc. Substituted melanocortin receptor-specific piperazine compounds
WO2004005324A2 (en) 2002-07-09 2004-01-15 Palatin Technologies, Inc. Peptide composition for treatment of sexual dysfunction
US7727991B2 (en) 2003-05-01 2010-06-01 Palatin Technologies, Inc. Substituted melanocortin receptor-specific single acyl piperazine compounds
US7727990B2 (en) 2003-05-01 2010-06-01 Palatin Technologies, Inc. Melanocortin receptor-specific piperazine and keto-piperazine compounds
US7968548B2 (en) 2003-05-01 2011-06-28 Palatin Technologies, Inc. Melanocortin receptor-specific piperazine compounds with diamine groups
KR20060026011A (ko) 2003-05-09 2006-03-22 노보 노르디스크 에이/에스 비만 치료용 펩티드
BRPI0409976A (pt) * 2003-05-09 2006-05-09 Novo Nordisk As composto, métodos para retardar a progressão de igt diabetes do tipo 2, para retardar a progressão de diabetes do tipo 2 para diabetes que requer insulina, para tratar obesidade ou prevenir excesso de peso para regular o apetite para induzir saciedade, para prevenir ganho de peso após se ter tido sucesso em perder peso, para aumentar dispêndio de energia, para tratar uma doença ou estado e para tratar bulimia, composição farmacêutica, e, uso de um composto
EP1644023A2 (en) * 2003-06-19 2006-04-12 Eli Lilly And Company Melanocortin recptor 4(mc4) agonists and their uses
EP1644022A1 (en) * 2003-06-19 2006-04-12 Eli Lilly And Company Uses of melanocortin-3 receptor (mc3r) agonist peptides
US7084111B2 (en) 2003-06-23 2006-08-01 University Of Florida Research Foundation, Inc. Melanocortin receptor templates, peptides, and use thereof
EP1670815A2 (en) 2003-09-30 2006-06-21 Novo Nordisk A/S Melanocortin receptor agonists
US7550602B1 (en) * 2004-01-14 2009-06-23 Palatin Technologies, Inc. Small molecule compositions for sexual dysfunction
US6974187B2 (en) * 2004-01-28 2005-12-13 Tachi-S Co., Ltd. Vehicle seat structure
JP2007530674A (ja) * 2004-03-29 2007-11-01 イーライ リリー アンド カンパニー 連続注入によって投与されるメラノコルチン−４受容体（ｍｃ４ｒ）アゴニストペプチドの使用
PL1751273T3 (pl) * 2004-04-08 2011-07-29 Astellas Pharma Inc Związek WS727713
US7709484B1 (en) 2004-04-19 2010-05-04 Palatin Technologies, Inc. Substituted melanocortin receptor-specific piperazine compounds
CN101052650A (zh) * 2004-11-04 2007-10-10 诺和诺德公司 用于治疗肥胖的新颖的肽类
JP2008519006A (ja) * 2004-11-04 2008-06-05 ノボ ノルディスク アクティーゼルスカブ 肥満症の治療に使用するためのペプチド
US20110098213A1 (en) * 2004-11-04 2011-04-28 Novo Nordisk A/S Novel peptides for use in the treatment of obesity
CN101052649A (zh) * 2004-11-04 2007-10-10 诺和诺德公司 用于治疗肥胖的肽类
CN101203527A (zh) * 2005-05-31 2008-06-18 耶路撒冷希伯来大学伊森姆研究发展公司 主链环化的促黑皮质素激素（αMSH）类似物
WO2006135930A2 (en) * 2005-06-13 2006-12-21 Nastech Pharmaceutical Company Inc. Transmucosal delivery of peptide derivatives
US7671112B2 (en) * 2005-07-15 2010-03-02 3M Innovative Properties Company Method of making fluoropolymer dispersion
US20080015304A1 (en) 2006-07-13 2008-01-17 Klaus Hintzer Aqueous emulsion polymerization process for producing fluoropolymers
GB2430437A (en) * 2005-09-27 2007-03-28 3M Innovative Properties Co Method of making a fluoropolymer
US7834017B2 (en) 2006-08-11 2010-11-16 Palatin Technologies, Inc. Diamine-containing, tetra-substituted piperazine compounds having identical 1- and 4-substituents
CA2673229A1 (en) * 2006-12-29 2008-07-10 F. Hoffmann-La Roche Ag Methods for the synthesis of cyclic peptides
EP2132143B1 (en) * 2007-02-16 2012-12-26 3M Innovative Properties Company System and process for the removal of fluorochemicals from water
US20080264864A1 (en) 2007-04-27 2008-10-30 3M Innovative Properties Company PROCESS FOR REMOVING FLUORINATED EMULSIFIER FROM FLUOROPOLMER DISPERSIONS USING AN ANION-EXCHANGE RESIN AND A pH-DEPENDENT SURFACTANT AND FLUOROPOLYMER DISPERSIONS CONTAINING A pH-DEPENDENT SURFACTANT
TWI364290B (en) * 2007-05-25 2012-05-21 Ipsen Pharma Sas Melanocortin receptor ligands modifled with hydantoin
WO2009011261A1 (ja) 2007-07-19 2009-01-22 Tokuyama Corporation ヒダントイン環を有する化合物及びその製造方法
AU2009228637B2 (en) * 2008-03-27 2013-12-19 Grunenthal Gmbh (Hetero-)aryl cyclohexane derivatives
CA2719735A1 (en) 2008-03-27 2009-10-01 Gruenenthal Gmbh Substituted 4-aminocyclohexane derivatives
WO2009151383A1 (en) * 2008-06-09 2009-12-17 Palatin Technologies, Inc. Melanocortin receptor-specific peptides for the treatment of obesity and other diseases associated with melanocortin receptor function
KR101687037B1 (ko) 2008-06-09 2016-12-15 팔라틴 테크놀로지스 인코포레이티드 성기능 장애 치료용 멜라노코르틴 수용체-특이적 펩티드
CA2761607C (en) * 2009-06-08 2018-09-04 Yi-Qun Shi Melanocortin receptor-specific peptides
EP2440572B1 (en) 2009-06-08 2017-04-05 Palatin Technologies, Inc. Lactam-bridged melanocortin receptor-specific peptides
UY32690A (es) 2009-06-08 2011-01-31 Astrazeneca Ab Péptidos específicos para receptores de melanocortina
BR112012011780A2 (pt) 2009-11-23 2019-09-24 Palatin Technologies, Inc peptídeo linear,composição farmacêutica,métodopara tratamento de umadoença,indicação,condição ou sídrome mediadsa por receptor de melanocortina emum mamífero humano ou não humano e método para tratamento de uma condição responsiva ás alterações em função de receptor de melanocortina em um mamifero humano ou não humano
JP5999702B2 (ja) 2009-11-23 2016-09-28 パラティン テクノロジーズ, インコーポレイテッドPalatin Technologies, Inc. メラノコルチン−１受容体特異的環状ペプチド
EP2970388B1 (en) 2013-03-15 2018-07-25 Rhythm Pharmaceuticals, Inc. Peptide compositions
GB201416352D0 (en) * 2014-09-16 2014-10-29 Shire Internat Gmbh Spirocyclic derivatives
GB201416351D0 (en) * 2014-09-16 2014-10-29 Shire Internat Gmbh Heterocyclic derivatives
CU20170038A7 (es) * 2014-09-26 2017-10-05 Bayer Pharma AG Derivados de adrenomedulina estabililzados especialmente útiles en el tratamiento y/o prevención de trastornos cardiovasculares, edematosos y/o inflamatorios
US10653743B2 (en) 2015-10-15 2020-05-19 Arizona Board Of Regents On Behalf Of The University Of Arizona Methods for the treatment of depression and anxiety by a melanocortin 5 receptor antagonist, PG-20N
US11542302B2 (en) 2015-10-15 2023-01-03 Arizona Board Of Regents On Behalf Of The University Of Arizona Modulators of melanocortin receptors for the treatment of depression and anxiety
WO2018074999A1 (en) * 2016-10-17 2018-04-26 The Arizona Board Of Regents On Behalf Of The University Of Arizona Novel modulators of melanocortin receptors for the treatment of depression and anxiety
US10899793B2 (en) 2016-05-27 2021-01-26 Regents Of The University Of Minnesota Melanocortin ligands and methods of use thereof
US11124541B2 (en) 2016-10-18 2021-09-21 Regents Of The University Of Minnesota Chimeric melanocortin ligands and methods of use thereof
US10745444B2 (en) * 2017-04-17 2020-08-18 National Tsing Hua University Cyclopeptide, pharmaceutical or cosmetic composition comprising the same and method for preparing the same
US11332499B2 (en) 2018-08-16 2022-05-17 Regents Of The University Of Minnesota Cyclic peptides and methods of use thereof
CN118530294B (zh) * 2024-05-10 2025-02-14 浙江大学 一种芳基二胺固载连接子、其前体以及制备方法和应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5731408A (en) * 1995-04-10 1998-03-24 Arizona Board Of Regents On Behalf Of The University Of Arizona Peptides having potent antagonist and agonist bioactivities at melanocortin receptors
WO1998037097A1 (en) * 1997-02-21 1998-08-27 Wapharm Ab Msh-receptor subtype selective cyclic peptides

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4237456A1 (de) * 1992-11-06 1994-05-11 Merck Patent Gmbh Cyclopeptide
US5811391A (en) 1994-08-25 1998-09-22 Cytel Corporation Cyclic CS-1 peptidomimetics, compositions and methods of using same
US5858972A (en) 1996-01-11 1999-01-12 La Jolla Cancer Research Foundation Antithrombotic agents and methods of use
CA2368431C (en) 1999-03-29 2006-01-24 The Procter & Gamble Company Melanocortin receptor ligands

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5731408A (en) * 1995-04-10 1998-03-24 Arizona Board Of Regents On Behalf Of The University Of Arizona Peptides having potent antagonist and agonist bioactivities at melanocortin receptors
WO1998037097A1 (en) * 1997-02-21 1998-08-27 Wapharm Ab Msh-receptor subtype selective cyclic peptides

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106496005A (zh) * 2016-10-20 2017-03-15 上海毕得医药科技有限公司 一种4‑(4‑氯苯基)环己酮的合成方法
CN106496008A (zh) * 2016-10-20 2017-03-15 上海毕得医药科技有限公司 一种合成4‑(4‑氯苯基)环己酮的方法
CN106496005B (zh) * 2016-10-20 2019-04-09 上海毕得医药科技有限公司 一种4-(4-氯苯基)环己酮的合成方法

Also Published As

Publication number Publication date
HUP0303078A3 (en) 2012-02-28
DK1315750T3 (da) 2007-06-11
KR100483300B1 (ko) 2005-04-15
SI1315750T1 (sl) 2007-06-30
BR0113637A (pt) 2004-02-25
JP2004507558A (ja) 2004-03-11
ECSP034503A (es) 2003-04-25
CA2420058C (en) 2009-04-07
CA2420058A1 (en) 2002-03-07
IL154575A0 (en) 2003-09-17
JO2454B1 (en) 2008-10-09
HUP0303078A2 (hu) 2003-12-29
TWI248941B (en) 2006-02-11
MXPA03001721A (es) 2003-05-27
ATE353918T1 (de) 2007-03-15
WO2002018437A3 (en) 2002-06-06
AU8402601A (en) 2002-03-13
US7045591B2 (en) 2006-05-16
US20020143141A1 (en) 2002-10-03
AR030504A1 (es) 2003-08-20
AU2001284026B2 (en) 2007-03-01
NO20030916L (no) 2003-02-27
DE60126624T2 (de) 2007-11-22
EP1315750A2 (en) 2003-06-04
HRP20030126B1 (en) 2009-01-31
CZ2003584A3 (cs) 2003-08-13
MY137457A (en) 2009-01-30
WO2002018437A2 (en) 2002-03-07
KR20030061788A (ko) 2003-07-22
PA8527201A1 (es) 2002-04-25
EP1315750B1 (en) 2007-02-14
CY1106562T1 (el) 2012-01-25
NO20030916D0 (no) 2003-02-27
YU15603A (sh) 2006-05-25
AR061422A2 (es) 2008-08-27
MA27681A1 (fr) 2006-01-02
PE20020483A1 (es) 2002-06-06
PT1315750E (pt) 2007-05-31
DE60126624D1 (de) 2007-03-29
JP4217069B2 (ja) 2009-01-28
PL366630A1 (en) 2005-02-07
IL154575A (en) 2008-12-29
HRP20030126A2 (en) 2005-10-31
RU2239642C1 (ru) 2004-11-10
NZ523989A (en) 2004-08-27
CN1451017A (zh) 2003-10-22
ES2280393T3 (es) 2007-09-16
ZA200301015B (en) 2004-05-05

Similar Documents

Publication Publication Date Title
CN100491396C (zh) 选择性环肽
EP1272516B1 (en) Selective linear peptides with melanocortin-4 receptor (mc4-r) agonist activity
AU2001284026A1 (en) Cyclic peptides having melanocortin-4 receptor agonist activity
US5674839A (en) Cyclic analogs of alpha-MSH fragments
CA2368431C (en) Melanocortin receptor ligands
NZ580849A (en) Cyclic peptide cxcr4 antagonists
TW200848424A (en) Cyclic peptide melanocortin receptor ligands
CN102596228A (zh) 神经肽-2受体(y-2r)激动剂
US8709998B2 (en) Peptide vectors
JP2025508820A (ja) Ｃｒｆ２受容体アゴニスト及び治療法におけるそれらの使用
CA2405724C (en) Substance p analogs for the treatment of cancer
HK40095414A (en) Crf2 receptor agonists and their use in therapy
CN121285571A (zh) Glp-1/gip双重、glp-1/gcg双重和glp-1/gip/gcg三重受体激动剂
HK1059272A (en) Selective cyclic peptides
HK1142011A (en) Camptothecin-somatostatin conjugates

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1059272

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1059272

Country of ref document: HK

C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20090527

Termination date: 20110821